You are here

Article Text

Article menu
Download PDFPDF
PostScript
PostScript
Survival in Crohn’s disease-associated small bowel adenocarcinoma
  1. Paolo Giuffrida1,
  2. Alessandro Vanoli2,
  3. Antonio Di Sabatino1
  1. 1 First Department of Internal Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
  2. 2 Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
  1. Correspondence to Professor Antonio Di Sabatino, First Department of Internal Medicine, Università degli Studi di Pavia Facoltà di Medicina e Chirurgia, PV, Lombardia 27100, Italy; a.disabatino{at}smatteo.pv.it

http://dx.doi.org/10.1136/gutjnl-2020-322364

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the recent work by Axelrad et al 1 dealing with small bowel cancer-related death rate in patients with inflammatory bowel disease. The authors concluded that small bowel cancer mortality is higher in Crohn’s disease (CrD) patients than in sporadic cases. However, the latter data are not in keeping with all studies published so far showing a similar death rate between patients with CrD-associated small bowel adenocarcinoma (CrD-SBA) and those with sporadic SBA (table 1). In particular, Palascak-Juif et al 2 demonstrated a slightly, but not significantly, higher survival rate, in CrD-SBAs (54% at 2 years and 35% at 5 years) than in sporadic SBAs …

    View Full Text

    Footnotes

    • Contributors PG, AV and ADS participated in the drafting of the manuscript or critical revision of the manuscript for important intellectual content, and provided approval of the final submitted version.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles